Healthy users, healthy adherers, and healthy behaviors?

Journal of Bone and Mineral Research

Volumn 26, Issue 4, 2011, Pages 681-682

  Silverman, Stuart L ^a   Gold, Deborah T ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CALCITONIN; ESTROGEN; GESTAGEN; VITAMIN D;

BONE DENSITY; CARDIOVASCULAR DISEASE; COMORBIDITY; HEALTH BEHAVIOR; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; NOTE; OBSERVATIONAL STUDY; OSTEOPOROSIS; SUPPLEMENTATION; VERTEBRA FRACTURE;

BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HEALTH BEHAVIOR; HIP FRACTURES; HUMANS; MEDICATION ADHERENCE; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 79953038078     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.384     Document Type: Note

References (18)

1. Curtis JR, Delzell E, Chen L, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the Fracture Intervention Trial. J Bone Miner Res. 26: 683-688.
2. Shrank WH, Patrick AR, Brookhart MA,. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. Published online January 4, 2011; DOI 10.1007/s11606-010-1609-1.
3. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and heart disease. N Engl J Med. 1985; 313: 1044-1049. (Pubitemid 16243331)
4. Varas-Lorenzo C, Garcia Rodriaguez LA, Perez Gutthann S, et al. Hormone replacement therapy and incidence of acute myocardial infarction: a population based nested case control study. Circulation. 2000; 101: 2572-2578. (Pubitemid 30350634)
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280: 605-613. (Pubitemid 28502636)
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333. (Pubitemid 34761611)
7. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007; 166: 348-354. (Pubitemid 47216808)
8. Dublin S, Jackson ML, Nelson JC, et al. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. Published online June 16, 2009; DOI 10.1136/bmj.b2137.
9. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009; 119: 2051-2057.
10. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med. 1980; 303: 1038-1041.
11. Horwitz RJ, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990; 336: 542-545. (Pubitemid 20278106)
12. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005; 366: 2005-2011. (Pubitemid 41773375)
13. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333: 15-18. (Pubitemid 44406838)
14. Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009; 47: 334-341.
15. Cadarette SM, Solomon DH, Katz JN, et al. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011; 22: 943-954.
16. Glynn RK, Schneeweiss S, Wang PS, et al. Selective prescribing led to overestimation of the benefits of lipid lowering drugs. J Clin Epidemiol. 2006; 59: 819-828. (Pubitemid 44040877)
17. Foster SA, Foley KA, Meadows ES, et al. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health. 2008: 24.
18. Silverman SL, Gold DT, Conditt MK, et al. Bone health behaviors and self-efficacy: an analysis based on Choices for Better Bone Health [abstract]. J Bone Miner Res. 2002; 17: S272.